Aharon Gal

Chief Strategy & Growth Officer · Novartis

Pharmaceuticals

Aharon Gal, also known as Ronny Gal, is Novartis’s chief strategy and growth officer. His background combines biochemistry, healthcare consulting, life-sciences business development and pharmaceutical equity research.

Last reviewed: Nov 15, 2026

Executive Summary

Aharon Gal, also known as Ronny Gal, is Novartis’s chief strategy and growth officer. His background combines biochemistry, healthcare consulting, life-sciences business development and pharmaceutical equity research.

Career Highlights

  • Joined Novartis in July 2022 to lead strategy and growth.
  • Spent much of his earlier career covering pharmaceutical companies at Sanford Bernstein.
  • Previously worked at Boston Consulting Group and Canon US Life Sciences.

Professional Journey

Gal earned a chemistry bachelor’s degree at Emory and a biochemistry doctorate at MIT. From 1996 to 2002 he worked at Boston Consulting Group in the United States, Singapore and China, progressing through consulting, team-lead and management positions focused largely on healthcare.

He became a vice president at Canon US Life Sciences in 2003 before moving to Sanford Bernstein in 2004. His initial research coverage centered on US specialty pharmaceuticals.

That coverage broadened over time to include European mid-cap pharmaceutical companies, biotechnology and, ultimately, the wider US biopharmaceutical industry. He was Bernstein’s senior US biopharmaceutical analyst from 2020 to 2022.

Gal joined Novartis in July 2022 as chief strategy and growth officer. Its annual report records an effective date of July 18. His present remit brings together corporate strategy, R&D portfolio strategy and business development, applying his scientific and financial-research background to the company’s portfolio decisions.

Education

Ph.D. — Massachusetts Institute of Technology — Biochemistry.

Bachelor of Science — Emory University — Chemistry.